UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination
Jiang Liu,Di Guan,Maogong Dong,Jingjing Yang,Haibin Wei,Qian Liang,Lizhi Song,Lu Xu,Junjie Bai,Cui Liu,Jian Mao,Qian Zhang,Junzhi Zhou,Xiaoying Wu,Miao Wang,Yu-Sheng Cong
DOI: https://doi.org/10.1038/s41556-020-0559-z
IF: 21.3
2020-08-17
Nature Cell Biology
Abstract:p53 is the most intensively studied tumour suppressor<sup><a href="/articles/s41556-020-0559-z#ref-CR1">1</a></sup>. The regulation of p53 homeostasis is essential for its tumour-suppressive function<sup><a href="/articles/s41556-020-0559-z#ref-CR2">2</a>,<a href="/articles/s41556-020-0559-z#ref-CR3">3</a></sup>. Although p53 is regulated by an array of post-translational modifications, both during normal homeostasis and in stress-induced responses<sup><a href="#ref-CR2">2</a>,<a href="#ref-CR3">3</a>,<a href="/articles/s41556-020-0559-z#ref-CR4">4</a></sup>, how p53 maintains its homeostasis remains unclear. UFMylation is a recently identified ubiquitin-like modification with essential biological functions<sup><a href="#ref-CR5">5</a>,<a href="#ref-CR6">6</a>,<a href="/articles/s41556-020-0559-z#ref-CR7">7</a></sup>. Deficiency in this modification leads to embryonic lethality in mice and disease in humans<sup><a href="#ref-CR8">8</a>,<a href="#ref-CR9">9</a>,<a href="#ref-CR10">10</a>,<a href="#ref-CR11">11</a>,<a href="/articles/s41556-020-0559-z#ref-CR12">12</a></sup>. Here, we report that p53 can be covalently modified by UFM1 and that this modification stabilizes p53 by antagonizing its ubiquitination and proteasome degradation. Mechanistically, UFL1, the UFM1 ligase<sup><a href="/articles/s41556-020-0559-z#ref-CR6">6</a></sup>, competes with MDM2 to bind to p53 for its stabilization. Depletion of UFL1 or DDRGK1, the critical regulator of UFMylation<sup><a href="/articles/s41556-020-0559-z#ref-CR6">6</a>,<a href="/articles/s41556-020-0559-z#ref-CR13">13</a></sup>, decreases p53 stability and in turn promotes cell growth and tumour formation in vivo. Clinically, UFL1 and DDRGK1 expression are downregulated and positively correlated with levels of p53 in a high percentage of renal cell carcinomas. Our results identify UFMylation as a crucial post-translational modification for maintenance of p53 stability and tumour-suppressive function, and point to UFMylation as a promising therapeutic target in cancer.
cell biology